|
61 |
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Enthalten in BioDrugs Bd. 27, 7.5.2013, Nr. 5, date:10.2013: 495-507
|
|
|
|
62 |
Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
Enthalten in BMC Rheumatology Bd. 6, 27.1.2022, Nr. 1, date:12.2022: 1-9
|
|
|
|
63 |
Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System
Enthalten in BioDrugs Bd. 37, 6.3.2023, Nr. 3, date:5.2023: 397-407
|
|
|
|
64 |
Similarity assessment by multivariate statistics method based on the distance between biosimilar and originator
Enthalten in Bioresources and Bioprocessing Bd. 8, 29.3.2021, Nr. 1, date:12.2021: 1-7
|
|
|
|
65 |
Single-cell RNA-seq data have prevalent blood contamination but can be rescued by Originator, a computational tool separating single-cell RNA-seq by genetic and contextual information
Enthalten in Genome biology Bd. 26, 11.3.2025, Nr. 1, date:12.2025: 1-13
|
|
|
|
66 |
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Enthalten in Biologics in therapy Bd. 3, 28.5.2013, Nr. 1, date:6.2013: 35-43
|
|
|
|
67 |
The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
Enthalten in Advances in therapy Bd. 37, 15.10.2020, Nr. 12, date:12.2020: 4831-4847
|
|
|
|
68 |
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
Enthalten in Biologics in therapy Bd. 4, 23.4.2014, Nr. 1-2, date:12.2014: 69-71
|
|
Administration
